146 related articles for article (PubMed ID: 10503729)
1. Chronic hepatitis B, biological basis for new therapeutic strategies.
Dianzani F
J Biol Regul Homeost Agents; 1999; 13(2):71-9. PubMed ID: 10503729
[No Abstract] [Full Text] [Related]
2. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.
Delaney WE; Yang H; Westland CE; Das K; Arnold E; Gibbs CS; Miller MD; Xiong S
J Virol; 2003 Nov; 77(21):11833-41. PubMed ID: 14557667
[TBL] [Abstract][Full Text] [Related]
3. [Current treatment of hepatitis B].
Suárez García E; Romero Gómez M; Grande Santamaría L
Gastroenterol Hepatol; 2001 Feb; 24 Suppl 1():35-50. PubMed ID: 11279893
[No Abstract] [Full Text] [Related]
4. Experience with lamivudine against hepatitis B virus.
Jaeckel E; Manns MP
Intervirology; 1997; 40(5-6):322-36. PubMed ID: 9675637
[TBL] [Abstract][Full Text] [Related]
5. Nucleoside analogues and other investigational modalities for the treatment of chronic hepatitis B.
Fried MW; Sommadossi JP
Antivir Ther; 1996 Apr; 1(2):71-6. PubMed ID: 11321182
[No Abstract] [Full Text] [Related]
6. Nucleoside analogues for chronic hepatitis B.
Wolters LM; Niesters HG; de Man RA
Eur J Gastroenterol Hepatol; 2001 Dec; 13(12):1499-506. PubMed ID: 11742201
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of famciclovir treatment in chronic hepatitis B patients with different mutations at position 552 of the DNA polymerase gene.
Wolters LM; Honkoop P; Niesters HG; de Man RA
J Hepatol; 1998 May; 28(5):909-10. PubMed ID: 9625328
[No Abstract] [Full Text] [Related]
8. [The efficacy of nucleoside/nucleotide analogue on chronic hepatitis B].
Lin Q; Zhang DZ
Zhonghua Gan Zang Bing Za Zhi; 2009 Oct; 17(10):722-5. PubMed ID: 19874684
[No Abstract] [Full Text] [Related]
9. Lamivudine and famciclovir treatment in HIV patients with acute hepatitis B virus infection and hepatitis B reactivation.
Panos GZ; Lampropoulos KM; Angelousi AG; Charatsis GG; Falagas ME
J Clin Gastroenterol; 2007 Feb; 41(2):222-3. PubMed ID: 17245225
[No Abstract] [Full Text] [Related]
10. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective.
Melegari M; Scaglioni PP; Wands JR
Hepatology; 1998 Feb; 27(2):628-33. PubMed ID: 9462667
[TBL] [Abstract][Full Text] [Related]
11. Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy.
Mutimer D; Pillay D; Cook P; Ratcliffe D; O'Donnell K; Dowling D; Shaw J; Elias E; Cane PA
J Infect Dis; 2000 Feb; 181(2):713-6. PubMed ID: 10669360
[TBL] [Abstract][Full Text] [Related]
12. Cell-mediated immune responses and loss of hepatitis B e-antigen (HBeAg) during successful lamivudine and famciclovir combination therapy for chronic replicating hepatitis B virus infection.
Hultgren C; Weiland O; Milich DR; Sällberg M
Clin Infect Dis; 1999 Dec; 29(6):1575-7. PubMed ID: 10585820
[No Abstract] [Full Text] [Related]
13. [New antiviral agents in the treatment of chronic hepatitis B and C].
Olaso Peiró V; López Viedma B; Córdoba Cortijo J
Rev Esp Enferm Dig; 1998 Apr; 90(4):291-304. PubMed ID: 9623272
[TBL] [Abstract][Full Text] [Related]
14. Chronic hepatitis B: interferon-monotherapy or combination with nucleoside analogues?
Tassopoulos NC
Liver; 1998 Apr; 18(2):71-2. PubMed ID: 9588765
[No Abstract] [Full Text] [Related]
15. Enhanced antiviral benefit of combination therapy with lamivudine and famciclovir against WHV replication in chronic WHV carrier woodchucks.
Korba BE; Cote P; Hornbuckle W; Schinazi R; Gerin JL; Tennant BC
Antiviral Res; 2000 Jan; 45(1):19-32. PubMed ID: 10774587
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of lamiduvine-resistant mutant chronic hepatitis B with interferon alpha].
Pariente A; Tachet A; Poveda JD
Gastroenterol Clin Biol; 2002 Nov; 26(11):1059-60. PubMed ID: 12483147
[No Abstract] [Full Text] [Related]
17. Prevention of hepatocellular carcinoma.
Wands JR
N Engl J Med; 2004 Oct; 351(15):1567-70. PubMed ID: 15470221
[No Abstract] [Full Text] [Related]
18. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.
Nafa S; Ahmed S; Tavan D; Pichoud C; Berby F; Stuyver L; Johnson M; Merle P; Abidi H; Trépo C; Zoulim F
Hepatology; 2000 Nov; 32(5):1078-88. PubMed ID: 11050059
[TBL] [Abstract][Full Text] [Related]
19. Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy.
Kim JW; Lee HS; Woo GH; Yoon JH; Jang JJ; Chi JG; Kim CY
Clin Infect Dis; 2001 Aug; 33(3):403-5. PubMed ID: 11438912
[TBL] [Abstract][Full Text] [Related]
20. Variant of hepatitis B virus with primary resistance to adefovir.
Schildgen O; Sirma H; Funk A; Olotu C; Wend UC; Hartmann H; Helm M; Rockstroh JK; Willems WR; Will H; Gerlich WH
N Engl J Med; 2006 Apr; 354(17):1807-12. PubMed ID: 16641397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
